Evaluation of the Performance of Investigational Contact Lenses in a Presbyopic Population

June 18, 2018 updated by: Johnson & Johnson Vision Care, Inc.
The objective of this study is to evaluate the performance of a novel multifocal lens system.

Study Overview

Status

Completed

Conditions

Study Type

Interventional

Enrollment (Actual)

298

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • California
      • Mission Viejo, California, United States
    • Florida
      • Jacksonville, Florida, United States
      • Jacksonville, Florida, United States
        • RPS
      • Saint Augustine, Florida, United States
      • Tallahassee, Florida, United States
      • Winter Park, Florida, United States
    • Georgia
      • Roswell, Georgia, United States
    • Maryland
      • Lutherville, Maryland, United States
    • New Jersey
      • Closter, New Jersey, United States
    • New York
      • New York, New York, United States
    • North Carolina
      • Denver, North Carolina, United States
    • Ohio
      • Athens, Ohio, United States
    • Pennsylvania
      • Kingston, Pennsylvania, United States
    • Rhode Island
      • Warwick, Rhode Island, United States
    • Tennessee
      • Memphis, Tennessee, United States
    • Texas
      • Amarillo, Texas, United States
      • Tyler, Texas, United States
    • Utah
      • Salt Lake City, Utah, United States
    • Virginia
      • Salem, Virginia, United States

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

36 years to 66 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  1. Subjects must read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a fully executed copy of the form.
  2. Subjects must appear able and willing to adhere to the instructions set forth in the clinical protocol.
  3. Subjects must be between 40 and 70 years of age.
  4. Subjects' spherical equivalent distance refraction must be in the range of -3.75 to +3.75 in each eye.
  5. Subjects' refractive cylinder must be less than or equal to 0.75D in each eye.
  6. Subjects' ADD power must be in the range of +0.75 to +2.50D in each eye.
  7. Subjects' must have the best corrected visual acuity of 20/20-3 or better in each eye.
  8. Subjects' should own a wearable pair of spectacles.
  9. Subjects' must be an adapted soft contact lens wearer in both eyes (i.e. worn lenses a minimum of 2 days per week for at least 8 hours per wear day, for 1 month or more duration).
  10. Subjects' must respond positively to at least on symptom on the "Presbyopis Symptoms Questionnaire" or already be wearing a presbyopic contact lens correction (e.g. reading spectacles over contact lenses, multifocal or monovision contact lenses, etc.).

Exclusion Criteria:

  1. Currently pregnant or lactating (subjects who become pregnant during the study will be discontinued).
  2. Any ocular or systemic allergies or diseases that may interfere with contact lens wear.
  3. Any systemic disease, autoimmune disease, or use of medication, which may interfere with contact lens wear.
  4. Any previous intraocular surgery (e.g. radial keratotomy, PRK, LASIK, etc.)
  5. Any grade 3 or greater slit lamp findings (e.g. edema, corneal neovascularization, corneal staining, tarsal abnormalities, conjunctival injection) which may contraindicate contact lens wear.
  6. Any ocular infection.
  7. Any corneal distortion resulting from previous hard or rigid gas permeable contact lens wear.
  8. History of binocular vision abnormality or strabismus.
  9. Any infectious disease (e.g. hepatitis, tuberculosis) or contagious immunosuppressive disease (e.g. HIV).
  10. History of diabetes.
  11. Participation in any contact lens or lens care product clinical trial within 7 days prior to study enrollment.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: etafilcon A/lotrafilcon B
Subjects were randomized to one of two lens wear sequences. Subject randomized to this sequence first wore the etafilcon A lens and then wore the lotrafilcon B lens.
To be worn in a daily wear modality for a minimum of 6 hours per day.
Lenses will be worn in a reuseable modality; cleaned and disinfected each night.
Other Names:
  • AirOptix Aqua Multifocal
Active Comparator: lotrafilcon B/etafilcon A
Subjects were randomized to one of two lens wear sequences. Subject randomized to this sequence first wore the lotrafilcon B lens and then wore the etafilcon A lens.
To be worn in a daily wear modality for a minimum of 6 hours per day.
Lenses will be worn in a reuseable modality; cleaned and disinfected each night.
Other Names:
  • AirOptix Aqua Multifocal

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Binocular Distance Visual Acuity (LogMAR)
Time Frame: 8-12 days post wear
Distance time controlled LogMAR Visual Acuity was carried out binocularly with high luminance and high contrast, at 4m under 250 cd/m^2. The test was presented under the condition High luminance (250 cd/m^2) High Contrast (90%)
8-12 days post wear
Binocular Near Visual Acuity (logMAR)
Time Frame: 8-12 days post wear
Near time controlled LogMAR Visual Acuity was carried out binocularly using High lumiance and High Contrast, at 40cm under 250 cd/m^2. The test was presented under the condition High Luminance (250cd/m^2) High Contrast (90%).
8-12 days post wear
Percentage of Eyes With Corneal Staining Grade 3 or Higher
Time Frame: 8-12 days post wear
Corneal staining was evaluated in 5 corneal regions (Central, Inferior, Nasal, Temporal and Superior) using Sodium Fluorescein strips. The Fluorescien strip was lightly placed on the subject's inferior palpebral conjunctiva. The corneal Staining was graded using the scale Grade 0: No Staining, Grade 1: Trace(Minimal superficial staining or stippling), Grade 2: Mild (Regional or diffuse punctate staining), Grade 3:Moderate(Significant dense coalesced staining, corneal abrasion or foreign body tracks.), Grade 4 Severe(Severe abrasions greater than 2 mm in diameter, ulcerations, epithelial loss, or full thickness abrasion.). The data was dichotomized into two group subjects with grade 3 or higher and those subjects with less than Grade 3 for the maximum grade of corneal staining across all 5 regions.
8-12 days post wear
Percentage of Eyes With Limbal Conjunctival Redness Grade 3 or Higher
Time Frame: 8-12 days post wear
The Limbus refers to the 1 to 2mm wide zone of conjunctiva and underlying tissue adjacent to where the cornea joins the sclera. Limbal Conjuctival Redness was graded in 4 regions (Nasal, Temporal, Inferior and Superior) using the Efron Grading Scale in 1 unit increments. Grade 0: Normal, Grade 1: Trace, Grade 2: Mild, Grade 3: Moderate, Grade 4: Severe. The data was dichotomized into two group subjects with grade 3 or higher Limbal Conjuctival Redness, and those subjects with less than Grade 3 for the maximum grade of all 4 regions.
8-12 days post wear
Percentage of Eyes With Bulbar Conjunctival Redness Grade 3 or Higher
Time Frame: 8-12 days post wear
Bulbar Conjunctival Injection was assessed in 4 regions (Nasal, Temporal, Inferior and Superior) using an Efron Grading scale by 1 unit increments. Grade 0: Normal, Grade 1: Trace, Grade 2: Mild, Grade 3: Moderate, Grade 4:Severe. The data was dichotomized into two group subjects with grade 3 or higher Conjunctival injection, and those subjects with less than Grade 3 for the maximum grade of all 4 regions.
8-12 days post wear
CLUE Overall Quality of Vision Using the Contact Lens User Experience (CLUE)TM Questionnaire
Time Frame: 8-12 days post wear
CLUE Overall Quality of Vision is assessed using the Contact Lens User Experience (CLUE)TM questionnaire. CLUE is a validated patient-reported outcomes questionnaire to assess patient experience attributes of soft, disposable contact lenses (comfort, vision, handling, and packaging) in a contact-lens wearing population in the US, ages 18-65. Scores follow a normal distribution with a population average score of 60 (SD 20), where higher scores indicate a more favorable/positive response. 97% of the scores fall within 0 and 120 (mean +/-3XSD).
8-12 days post wear

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

November 1, 2012

Primary Completion (Actual)

February 1, 2013

Study Completion (Actual)

February 1, 2013

Study Registration Dates

First Submitted

December 17, 2012

First Submitted That Met QC Criteria

January 4, 2013

First Posted (Estimate)

January 8, 2013

Study Record Updates

Last Update Posted (Actual)

June 19, 2018

Last Update Submitted That Met QC Criteria

June 18, 2018

Last Verified

May 1, 2016

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CR-5357

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Presbyopia

Clinical Trials on etafilcon A

Subscribe